Juniper Biosciences Wins FDA Breakthrough Therapy Designation for JBS-003
核心洞察
Juniper Biosciences (搜索) received FDA Breakthrough Therapy Designation for JBS-003 (搜索) (18F-fluoromisonidazole, or FMISO), a first-in-class hypoxia tracer developed with Memorial Sloan Kettering Cancer Center.
The radiopharmaceutical is intended to identify tumor hypoxia (搜索) and guide de-escalated radiation therapy in patients with HPV-positive oropharyngeal carcinoma (搜索), sparing them high-dose radiation side effects.
MSK licensed the supporting clinical trial data to Juniper earlier this year and is now running a randomized, double-blind Phase 3 trial (NCT06563479) of FMISO-selected de-escalated radiation therapy.
Juniper Biosciences (搜索) has received U.S. Food and Drug Administration (搜索) Breakthrough Therapy Designation for JBS-003 (搜索) (18F-fluoromisonidazole, or FMISO), a first-in-class hypoxia tracer. Memorial Sloan Kettering Cancer Center, which described Juniper as a key licensing partner, said the radiopharmaceutical is used to identify tumor hypoxia (搜索) to guide de-escalated radiation therapy in patients with HPV-positive oropharyngeal carcinoma (搜索) (OPC).
MSK licensed the clinical trial data supporting the tracer's use to Juniper earlier this year. The designation is reserved for programs intended to address a serious condition where preliminary clinical evidence indicates the potential for substantial improvement over available therapy on a clinically significant endpoint. MSK said its Radiation Oncology and Medical Physics teams generated foundational research, and earlier phases of Juniper's clinical trials were conducted at the center.
MSK is now conducting a Phase 3 trial (NCT06563479), a randomized, double-blind study evaluating FMISO-selected de-escalated radiation therapy. Nancy Y. Lee, a radiation oncologist and Service Chief for Head and Neck Oncology at MSK, said the center looks forward to completing the trial and generating the pivotal evidence needed to support potential FDA approval.
Source: OncoDaily